SUPERNUS PHARMACEUTICALS INC (SUPN) Stock News

USA - NASDAQ:SUPN - US8684591089 - Common Stock

49.075 USD

+0.7 (+1.44%)

Last: 10/14/2025, 1:05:50 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SUPN Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Chartmill

News Image

SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Represents an Affordable Growth Opportunity

a day ago - By: Zacks Investment Research

Supernus Pharmaceuticals (SUPN) Is Up 2.81% in One Week: What You Should Know

4 days ago - By: Zacks Investment Research - Mentions: NVS BIIB PTCT

Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?

5 days ago - By: Benzinga - Mentions: KTOS TSCO PNC SF ...

Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday

15 days ago - By: Benzinga - Mentions: FTXH MIXJ IHE PBE ...

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk

a month ago - By: Biogen Inc. - Mentions: BIIB

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

2 months ago - By: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals to Participate in September Investor Conferences

2 months ago - By: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals to Participate in September Investor Conferences

2 months ago - By: Yahoo Finance

Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN)

2 months ago - By: Zacks Investment Research

Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

2 months ago - By: Zacks Investment Research - Mentions: LXRX

Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates

2 months ago - By: Supernus Pharmaceuticals, Inc.

Supernus Announces Second Quarter 2025 Financial Results

2 months ago - By: Supernus Pharmaceuticals, Inc.

Supernus Announces Second Quarter 2025 Financial Results